Axial Spondyloarthritis Drug Market
Global Axial Spondyloarthritis Drug Market Size, Share & Trends Analysis Report By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, and Others), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period (2022-2028)
The global axial spondyloarthritis drug market is anticipated to grow at a significant CAGR of 4.1% during the forecast period. Increasing Chronic inflammatory back pain, combined with the stiffness of the pelvis and lower back among people, is the most common symptom of axial spondyloarthritis, which is driving the growth of the market. For instance, according to the information provided by American Chiropractic Association in 2022, 80% of the American population will suffer from lower back pain. Additionally, the availability of treatment options such as physiotherapy is expanding the growth of the market. However, a key factor impeding growth is the limited therapeutic choices associated with axial spondyloarthritis along with the high treatment costs and a lack of awareness in rural areas.
Impact of COVID-19 Pandemic on Global Axial Spondyloarthritis Drug Market
The global axial spondyloarthritis drug market is hardly hit by the COVID-19 Pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation across the globe. The COVID-19 pandemic had affected health care, however in order to discover more effective drugs strategic initiative has been done by various key market players which are providing effective recovery to the market.
Segmental Outlook
The global axial spondyloarthritis drug market is segmented based on type and distribution channel. Based on the type, the market is sub-segmented into the certolizumab pegol, etanercept biosimilar, ixekizumab, and others. Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies are anticipated to have a significant market share in the market. As the globe is becoming more digital, online pharmacies are likely to rise significantly in the axial spondyloarthritis drug market throughout the forecast period.
Global Axial Spondyloarthritis Drug Market Share by Type, 2021 (%)
Ixekizumab holds the Significant Market Share in the Global Axial Spondyloarthritis Drug Market
Ixekizumab is anticipated to have a significant market share in the axial spondyloarthritis drug market. Ixekizumab is a drug that is used to treat inflammatory arthritis such as psoriatic arthritis (PsA). When DMARD therapy has failed to provide a satisfactory response, ixekizumab is utilized. Methotrexate (MTX) or other standard DMARDs should be taken in conjunction with ixekizumab for effective results. Ixekizumab can also be used as a monotherapy for patients who are unable to tolerate MTX.
Regional Outlooks
The global axial spondyloarthritis drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Axial Spondyloarthritis Drug Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Axial Spondyloarthritis Drug Market
The Asia-Pacific region holds a significant share and is anticipated to grow fastest during the forecast period in the axial spondyloarthritis drug market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall axial spondyloarthritis drug market. Additionally, due to the expanding senior population, and improving health care infrastructure, Asia Pacific is expected to grow significantly in the axial spondyloarthritis drug market. According to the United Nations' World Population Prospects in 2019, India and China account for 36% of the global population.
Market Players Outlook
The major companies serving the global axial spondyloarthritis drug market include AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Novartis AG, Panacea Biotec Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, AbbVie Inc. announced favorable trial results for RINVOQTM (upadacitinib) for patients with moderate to severely active rheumatoid arthritis who do not respond to methotrexate therapy.
In June 2020, Health Canada had approved Eli Lilly and Company's Taltz injectable for the treatment of non-radiographic axial spondyloarthritis, psoriatic arthritis, and ankylosing spondylitis.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global axial spondyloarthritis drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Axial spondyloarthritis drug Market
• Recovery Scenario of Global Axial spondyloarthritis drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca Plc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Eli Lilly and Co.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Johnson & Johnson Services, Inc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis AG
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Panacea Biotec Ltd.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Axial Spondyloarthritis Drug Market by Type
4.1.1. Certolizumab Pegol
4.1.2. Etanercept Biosimilar
4.1.3. Ixekizumab
4.1.4. Others (Secukinumab)
4.3.Global Axial Spondyloarthritis Drug Market by Distribution Channel
4.3.1. Hospital Pharmacies
4.3.2 Retail Pharmacies
4.3.3 Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. AbbVie Inc.
6.3. Amgen Inc.
6.4. GlaxoSmithKLine Plc.
6.5. Kyowa Kirin Co., Ltd.
6.6. Merck & Co. Inc.
6.7. Pfizer Inc.
6.8. Sandoz International GmbH
6.9. KYOCERA Corp.
6.10. Sun Pharmaceutical Industries Ltd.
6.11. UCB S.A.
1. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CERTOLIZUMAB PEGOL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ETANERCEPT BIOSIMILAR AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL IXEKIZUMAB AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS DRUG IN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
7. GLOBAL HOSPITAL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RETAIL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ONLINE PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
14. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
16. EUROPEAN AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET, 2022-2028 (%)
4. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL CERTOLIZUMAB PEGOL ANTI-INFLAMMATORY DRUGS (NSAID) AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL ETANERCEPT BIOSIMILAR AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL IXEKIZUMAB AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OTHERS DRUG IN AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
10. GLOBAL HOSPITAL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL RETAIL PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ONLINE PHARMACIES AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL AXIAL SPONDYLOARTHRITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. UK AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD AXIAL SPONDYLOARTHRITIS DRUG MARKET SIZE, 2021-2028 ($ MILLION)
